Your session is about to expire
← Back to Search
Pembrolizumab for Cutaneous T-Cell Lymphoma
Study Summary
This trial will test if a new way of delivering the cancer drug pembrolizumab to patients with cutaneous T-cell lymphoma is feasible.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am willing to have two biopsies for this study.I have not had a transplant and am not eligible for one.I have had a stem cell or organ transplant in the past.I agree to use birth control during and for 4 months after the study.I am fully active or restricted in physically strenuous activity but can do light work.My organs are working well.My doctor says I have slow lymphatic flow due to a medical condition.My cancer is between stages IB and IIIB.I agree to use condoms during the study and for 4 months after the last dose.I do not have an active autoimmune disease, except for vitiligo, stable thyroid disease, or Type 1 diabetes.I have had at least one treatment for my cutaneous T-cell lymphoma.My cancer has spread extensively to my organs or blood.I have a history of lung scarring or fibrosis.My condition worsened during or after my last treatment.I have been treated with drugs targeting PD-L1 or PD-1 before.I have been diagnosed with Mycosis fungoides.I am 18 years old or older.You are currently using drugs or alcohol excessively.I need immediate treatment for myelofibrosis.
- Group 1: All participants
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Pembrolizumab been administered with the aid of Sofusa® DoseConnect™ in other research?
"Currently, 961 trials are being conducted involving the administration of Pembrolizumab with Sofusa® DoseConnect™. 122 of these medical studies are in Phase 3. 35731 locations across the world have been identified as sites for running this treatment-related research and Houston, Texas is a major hub."
What illnesses does the Sofusa® DoseConnect™ method of administering Pembrolizumab treat?
"Pembrolizumab delivered via Sofusa® DoseConnect™ is a common intervention for malignant neoplasms, as well as unresectable melanoma, microsatellite instability high, and cases of chemotherapy resistance."
How does the Sofusa® DoseConnect™ impact Pembrolizumab's risk profile for patients?
"Our team at Power provided a rating of 1 for the safety profile of Pembrolizumab administered using Sofusa® DoseConnect™, as this is the initial stage in clinical trials and there is scarce evidence to support its efficacy or protection."
Are enrollees currently being accepted into this clinical research?
"Affirmative. Visiting clinicaltrials.gov reveals that this experiment, which was originally advertised on August 31st 2022, is actively seeking participants. 10 individuals are necessary for the trial to be conducted at a single medical site."
How many participants are currently enrolled in this trial?
"Affirmative. The clinicaltrials.gov portal discloses that this trial, launched on August 31st 2022, is currently recruiting participants. A total of 10 individuals are needed to be enrolled at 1 site."
Share this study with friends
Copy Link
Messenger